Okomera

The core of Okomera's business model is its advanced 3D organoid screening technology. This technology allows for the testing of various potential cancer therapies—such as chemotherapy, immunotherapy, cell therapy, and combined therapies—on cells derived from a patient's tumor biopsy. These cells are cultured in 3D spheroids on a microfluidic chip, which is a small device that can control the flow of tiny amounts of fluids. This setup mimics the tumor's natural environment more accurately than traditional 2D cell cultures, leading to better predictions of how a patient will respond to different treatments.

Okomera integrates standard assays (tests) on these chips, including CRISPR (a gene-editing tool), T cell assays (tests that measure the activity of immune cells), and cytotoxicity assays (tests that measure how toxic a substance is to cells). This comprehensive approach accelerates drug discovery from the initial target identification to validation, and enhances preclinical predictivity, meaning it improves the accuracy of predicting how well a drug will work in clinical trials.

The company generates revenue by partnering with pharmaceutical companies and research institutions to provide its screening services. Additionally, Okomera may license its technology to other entities in the healthcare sector, creating multiple streams of income.

In December 2023, Okomera announced a successful fundraising of $10 million, which will be used to further develop its personalized medicine technologies. This financial boost underscores the market's confidence in Okomera's innovative approach to cancer treatment.